Navigation Links
Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

RCC), solid tumors, non small cell lung cancer (NSCLC) and selected hematologic malignancies such as leukemia.

PARP Inhibitors (veliparib) – Veliparib is an oral PARP-inhibitor that was discovered and developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase II studies in melanoma and breast cancer. Veliparib is also being studied in the I-SPY 2 breast cancer trial, led by the Foundation for the National Institutes of Health.

Bcl-2 Family Protein Inhibitors (navitoclax) – Navitoclax restores apoptosis or programmed cell death, a natural mechanism for the elimination of cancerous cells, by inhibiting the function of Bcl-2 proteins. Bcl-2 regulates apoptosis, as well as tumor formation and tumor growth, and can enable cancer cells to resistance to treatment. Navitoclax is in clinical trials for lymphomas and solid tumors, including small cell lung cancer. Additionally, preclinical data have shown that Bcl-2 family protein inhibitors have the potential to enhance the effects of chemotherapy and radiation used to treat other types of cancer, such as non-small cell lung cancer.

Elotuzumab (HuLuc63) – Elotuzumab is a humanized monoclonal antibody that binds to CS1, a cell-surface glycoprotein that is highly expressed on myeloma cells but minimally expressed on normal human cells. Abbott is developing elotuzumab for multiple myeloma in collaboration with Bristol-Myers Squibb Company.

Beyond pharmaceutical research, Abbott provides supportive care products and diagnostics related to oncology. The company offers a broad range of pharmaceutical and nutritional products to help people living with cancer, inclu
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. Abbotts Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
3. Abbotts Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
4. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
5. Assegai Wins Big Settlement Against ABBOTTs Subsidiary
6. Abbott 2009 Global Citizenship Report Highlights Companys Progress in Redefining Responsibility
7. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
8. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
9. Abbott Completes Acquisition of Facet Biotech
10. Abbott Completes Acquisition of STARLIMS Technologies
11. Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... WASHINGTON, June 15, 2011 A new ad campaign launched ... country have in finding savings for their state,s Medicaid program: ... drugstores. States and the federal government could save $33 ... overpayments and modernizing pharmacy benefits to be more like those ...
... 2011 MedNet Solutions, a global life sciences technology ... pleased to announce that MedNet will be showcasing its ... Drug Information Association (DIA) Annual Meeting in Chicago, IL ... the commercial release of iMedNet EDC earlier this year, ...
Cached Medicine Technology:The Medicaid Choice: Cut Benefits for Patients or Overpayments to Independent Drugstores 2MedNet Solutions to Showcase Its Complete Suite of eClinical Solutions at the 47th DIA Annual Meeting 2
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
(Date:12/26/2014)... 26, 2014 The US represents the largest ... In 2013, GlobalData’s forecast estimates that sales of branded therapies ... due to the high incidence of the disease, high drug ... Japan, and China. Increased sales of CRC therapies over the ...
(Date:12/26/2014)... December 26, 2014 Cooking and warming ... of 5. This score reflects slightly positive negotiation conditions for ... switching costs and a low level of price volatility. “However, ... for cooking and warming equipment and high volatility in the ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... offer a new way to detect and treat autism during ... months of life, when the brain is ... agree that,the earlier autism is diagnosed and therapy begun, the ... even when parents have an intuition,that "something is amiss" with ...
... Low Fat, Rich and Creamy Beverage ... FULLERTON, Calif., March 11 Wildwood Organics, a,division of ... today launched Probiotic Soymilk(TM). This delicious beverage is,certified organic, ... of soy protein per serving. Probiotic Soymilk(TM) is also ...
... a global,leader in dental and aesthetic lasers, today ... tissue lasers will receive a,tuition-free introductory laser certification ... dental laser education. The partnership is,the latest milestone ... education., "We fully recognize that training is ...
... and Phase II Trials, with Some Patients Already Past the Expected Median Average ... Survival Time for This Population -, - Data From Dosimetry Trial ... ... March 11 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ...
... March 10 As a longtime resident of Southern,Nevada, ... who have been,affected by this situation. I understand that ... against me and the Endoscopy Center of,Southern Nevada. While ... I,am unfortunately unable to do so at this time ...
... N.C., March 10 Cogdell Spencer,Inc. (NYSE: CSA ... 100,percent of the stock of Marshall Erdman and Associates. ... integrated healthcare real estate,company in the country, with over ... on January 23, 2008, was financed,through a $100 million ...
Cached Medicine News:Health News:Autism Awareness Month - New Hope for Detecting/Reversing Autism in Infants 2Health News:Wildwood Organics Introduces Probiotic Soymilk(TM) 2Health News:HOYA ConBio Partners With Advanced Laser Training to Offer Complementary Laser Certification Course in Dentistry 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 3Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 4Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 5Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 6Health News:Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger 2
... new highly sensitive and specific second-generation peptide-based ... on the detection of autoantibodies against the ... residues in human serum or plasma. Enabling ... Anti-CCP assay provides an additional tool in ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
Color-enhanced slide test for the rapid qualitative and semi-quantitative detection of antibodies to streptococcal extracellular antigens in serum, plasma and peripheral blood....
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Medicine Products: